文献速递胸部肿瘤消化系统肿瘤支持与姑息治疗

Ifinatamab deruxtecan(B7-H3抗体偶联药物)治疗晚期实体瘤的剂量递增研究

Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

IDeate-PanTumor01是一项首次人体、多中心、开放标签的1/2期研究,纳入97例经治晚期实体瘤患者,接受ifinatamab deruxtecan(0·8-16·0 mg/kg 每3周)治疗。剂量递增阶段未达到最大耐受剂量,确认的客观缓解率在可评估患者中为34%(95% CI 23-47)。常见≥3级治疗中出现的不良事件为贫血(18%),发生1例与研究药物相关的间质性肺病死亡。

要点

  • 剂量递增未达到最大耐受剂量,确认的ORR为34%(95%CI 23-47)。
  • 常见≥3级TEAE为贫血(18%)、中性粒细胞减少(4%)。
  • 发生1例与研究药物相关的间质性肺病死亡,需警惕并及时处理。

核心结论

  • Ifinatamab deruxtecan在多种晚期实体瘤中显示出抗肿瘤活性,但发生1例治疗相关间质性肺病死亡,需及时评估和谨慎管理。

研究设计与样本

  • 患者接受ifinatamab deruxtecan 0·8-16·0 mg/kg静脉给药,每3周一次。
  • 主要终点为剂量递增阶段的安全性,抗肿瘤活性为次要终点,在剂量≥4·8 mg/kg的患者中评估。

主要发现

  • 3例患者出现剂量限制性毒性;根据方案定义标准,未达到最大耐受剂量。
  • 最常见的≥3级治疗中出现的不良事件为贫血(17例,18%)、中性粒细胞减少(4例,4%)、淋巴细胞计数降低(3例,3%)和中性粒细胞计数降低(3例,3%)。
  • 严重治疗中出现的不良事件发生于31例(32%)患者;与死亡相关的治疗中出现的不良事件报告于5例(5%)患者(肺炎、吸入性肺炎、COVID-19肺炎、间质性肺病和1例未指定原因的死亡)。
  • 研究者认为间质性肺病导致的死亡与研究药物相关。
  • 中位随访8·6个月(IQR 4·1-12·9),跨瘤种确认的客观缓解率为34%(95% CI 23-47;70例可评估患者中24例)。

临床怎么用

  • Ifinatamab deruxtecan在多种实体瘤中显示 promising 抗肿瘤活性,支持进一步开展随机对照试验。
  • 临床应用时需警惕间质性肺病,对出现症状的患者及时评估和谨慎管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ifinatamab deruxtecan is a novel B7-H3-directed antibody-drug conjugate that leverages the clinically validated deruxtecan technology. We report dose-escalation results from a trial of ifinatamab deruxtecan in patients with solid tumours. METHODS: In this two-part, multicentre, open-label, first-in-human, phase 1/2 study of ifinatamab deruxtecan conducted at clinics in ten hospitals and cancer centres in the USA and Japan, we recruited patients aged 18 years or older who had advanced treatment-refractory solid tumours (small-cell lung cancer, oesophageal squamous cell carcinoma, castration-resistant prostate cancer, squamous non-small-cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, sarcoma, endometrial cancer, melanoma, or breast cancer), and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received ifinatamab deruxtecan at doses of 0·8-16·0 mg/kg intravenously every 3 weeks. The primary outcome of dose escalation was the safety profile, which was evaluated in patients who received one or more dose of ifinatamab deruxtecan. Antitumour activity (per Response Evaluation Criteria in Solid Tumours version 1.1; secondary outcome) was evaluated in patients receiving ifinatamab deruxtecan at doses of 4·8 mg/kg or higher. The data cutoff was Jan 31, 2023. This trial is registered with ClinicalTrials.gov (NCT04145622) and is ongoing. FINDINGS: Between Oct 25, 2019, and July 13, 2022, 97 patients were enrolled and treated. 77 (79%) patients were male and 20 (21%) were female, 56 (58%) patients were White, and 31 (32%) were Asian. Three patients (3%) had dose-limiting toxicities; however, on the basis of protocol-defined criteria, the maximum tolerated dose was not reached. The most common grade 3 or worse treatment-emergent adverse events (TEAEs) were anaemia (17 [18%] patients), neutropenia (four [4%]), lymphocyte count decreased (three [3%]), and neutrophil count decreased (three [3%]). Serious TEAEs occurred in 31 (32%) patients. TEAEs associated with death were reported in five patients (5%; pneumonia, pneumonia aspiration, COVID-19 pneumonia, interstitial lung disease, and one death of undesignated cause); death due to interstitial lung disease was considered related to study medication by the investigator. After a median follow-up of 8·6 months (IQR 4·1-12·9), the confirmed objective response rate across tumour types was 34% (95% CI 23-47; 24 of 70 evaluable patients). INTERPRETATION: The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials. FUNDING: Funding for this study was provided by Daiichi Sankyo Company (Daiichi Sankyo) and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ, USA.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson ML, Patel MR, Falchook GS, et al. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. Lancet Oncol. 2026. PMID: 41926962. doi:10.1016/S1470-2045(25)00733-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。